Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) has been beaten down lately with too much selling pressure. While the stock has lost 11% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier. Here is How to Spot Oversold Stocks We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This ...

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare Conference Date: June 11, 2024 Lo ...

BOSTON and LONDON, May 21, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its management team will participate in the following investor conferences: Event: Jefferies Global Healthcare Conference Date: June 6, 2024 Location: NY, NY Fireside Chat: 1:00 PM ET Event: Goldman Sachs 45th Annual Global Healthcare Conference Date: June 11, 2024 Lo ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40445 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98 ...

Exhibit 99.1 Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2024 BOSTON and LONDON, May 13, 2024: Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today reported financial results and business highlights for the first quarter ended March 31, 2024. "2024 is off to a strong start for Centessa. Following clearance of our IND, we recently in ...

Core Insights - Centessa Pharmaceuticals reported a strong start to 2024, initiating a Phase 1 clinical trial for ORX750, an orexin receptor 2 agonist for narcolepsy, and plans to share proof-of-concept data later this year [2][5] - The company is advancing three key pipeline programs targeting significant unmet medical needs, including hemophilia B and sleep-wake disorders, supported by a strengthened balance sheet [2][5] - Financial results for Q1 2024 show a net loss of $38.0 million, a decrease from $50.7 million in Q1 2023, with reduced operating expenses [13][17] Recent Highlights - The FDA cleared the IND for ORX750, allowing the initiation of the first-in-human clinical trial [6] - Data from the ongoing Phase 2a study of SerpinPC for hemophilia B showed a 96% reduction in the median annualized bleeding rate [6][10] - The company completed a public offering, raising approximately $107.2 million to support clinical operations [6][13] Anticipated Upcoming Program Milestones - Hemophilia Program: Ongoing registrational studies for SerpinPC, with an interim analysis of the PRESent-2 study planned for 2024 [5][10] - Orexin Agonist Program: Clinical proof-of-concept data for ORX750 expected in the second half of 2024 [5][7] - LockBody Technology Platform: Ongoing Phase 1/2a study of LB101 for solid tumors [5][12] Financial Overview - Cash, cash equivalents, and short-term investments totaled $230.2 million as of March 31, 2024, expected to fund operations into mid-2026 [13][18] - Research and development expenses decreased to $22.7 million in Q1 2024 from $32.8 million in Q1 2023 [13][17] - General and administrative expenses also decreased to $13.4 million in Q1 2024 from $16.1 million in Q1 2023 [13][17]

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares ("ADSs"), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $1 ...

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares ("ADSs"), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purc ...

BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administered, highly potent and s ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-40445 CENTESSA PHARMACEUTICALS PLC (Exact name of registrant as specified in its charter) England and Wales 98-1612 ...